{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Group', 'Adverse Event', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Skin', 'Erythema multiforme', 'Target lesions covering', 'Target lesions covering 10 -', 'Target lesions covering', 'Target lesions covering', '< 10% BSA and not', '30% BSA and associated', '> 30% BSA and', '> 30% BSA; associated', 'associated with skin', 'with skin tenderness', 'associated with oral or', 'with fluid or electrolyte', 'tenderness', 'genital erosions', 'abnormalities; ICU care', 'or burn unit indicated', 'Definition: A disorder characterized by target lesions (a pink-red ring around a pale center).', 'Palmar-plantar', 'Minimal skin changes or', 'Skin changes (e.g., peeling,', 'Severe skin changes', '-', 'erythrodysesthesia', 'dermatitis', 'blisters, bleeding, edema, or', '(e.g., peeling, blisters,', 'syndrome', '(e.g., erythema, edema, or', 'hyperkeratosis) with pain;', 'bleeding, edema, or', 'hyperkeratosis) without', 'limiting instrumental ADL', 'hyperkeratosis) with', 'pain', 'pain; limiting self-care', 'ADL', 'Definition: A disorder characterized by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet.', 'Photosensitivity', 'Painless erythema and', 'Tender erythema covering', 'Erythema covering', 'Life-threatening', 'erythema covering < 10%', '10 - 30% BSA', '> 30% BSA and', 'consequences; urgent', 'BSA', 'erythema with blistering;', 'intervention indicated', 'photosensitivity; oral', 'corticosteroid therapy', 'indicated; pain control', 'indicated (e.g., narcotics', 'or NSAIDs)', 'Definition: A disorder characterized by an increase in sensitivity of the skin to light.', '140']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Group', 'Adverse Event', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Skin', 'Rash maculo-papular', 'Macules/papules', 'Macules/papules covering', 'Macules/papules', '-', '(cont.)', 'covering < 10% BSA', '10 - 30% BSA with or', 'covering > 30% BSA', 'with or without', 'without symptoms', 'with or without', 'symptoms (e.g., pruritus,', '(e.g., pruritus, burning,', 'associated symptoms;', 'burning, tightness)', 'tightness); limiting', 'limiting self-care ADL', 'instrumental ADL', 'Definition: A disorder characterized by the presence of macules (flat) and papules (elevated). Also known as morbillform rash, it is one of the', 'most common cutaneous adverse events, frequently affecting the upper trunk, spreading centripetally and associated with pruritus.', 'Cross reference: NCI CTCAE version 4.011', '141']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix I.', 'Fluid Retention Questionnaire', 'Fluid Retention Questionnaire for Study M16-298', 'Subject ID:', 'Over the past 7 days, or since the last time this questionnaire was completed:', '1.', 'What has your daily weight been?', 'Please weigh yourself at the same time each day and record the date and your', 'weight for that day below. Weight should be taken without outer garments', 'such as hats, coats or shoes. Measurements while in light indoor clothing only,', 'or undergarments only, are acceptable; however, please try to use the same or', 'similar clothing (including any accessories or jewelry) from day to day when', 'measuring weight.', 'Please complete one questionnaire for every 7 day/1 week period.', 'Date (DD/MMM/YYYY)', 'Weight (Circle One: lb or kg)', 'lb or kg', 'lb or kg', 'lb or kg', 'lb or kg', 'lb or kg', 'lb or kg', 'lb or kg', '2.', 'Have you noticed any new or worsening edema - e.g., swelling of the ankles or', 'legs during the days above?', 'Yes or', 'No', '3.', 'Have you noticed any new or worsening shortness of breath during the days above?', 'Yes or', 'No', '142']\n\n###\n\n", "completion": "END"}